Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable HPV-16 Cancer

This phase 2 clinical trial examines whether the efficacy of nivolumab is amplified through treatment with ISA 101, a synthetic long-peptide human papillomavirus 16 vaccine, in patients with incurable human papillomavirus 16–positive cancer.

https://ift.tt/2N4oaWE